While every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described within this Journal, should only be followed in conjunction with the drug manufacturer s own published literature. SUPPLEMENTARY MATERIAL Supplemental Table 1: Summary table of RCT examining the effect of exercise in CKD 5HD patients [continuous outcomes] Supplemental Table 2: Summary table of RCT examining low vs. mode- rate protein diet in CKD patients without DM [categorical outcomes] Supplemental Table 3: Summary table of RCT examining low vs. mode- rate protein diet in CKD patients without DM [continuous outcomes] Supplemental Table 4: Summary table of RCT examining statin therapy vs. lifestyle modification in kidney transplant recipients without DM [categorical outcomes] Supplemental Table 5: Summary table of RCT examining statin therapy vs. lifestyle modification in kidney transplant recipients without DM [continuous outcomes] Supplemental Table 6: Summary table of RCT examining statin therapy vs. usual care in patients with CKD without DM [categorical outcomes] Supplemental Table 7: Summary table of RCT examining statin therapy vs. usual care in patients with CKD without DM [continuous outcomes] Supplemental Table 8: Summary table of RCTs of statins vs. placebo in patients with CKD with and without DM [categorical outcomes] Supplemental Table 9: Summary table of RCTs of statins vs. placebo in various stages of CKD with and without DM [continuous outcomes] Supplemental Table 10: Evidence profile of RCTs examining the effect of statins vs. placebo in patients with CKD with and without DM Supplemental Table 11: Summary table of RCTs of statins vs. placebo in dialysis patients with and without DM [categorical outcomes] Supplemental Table 12: Summary table of RCTs of statins vs. placebo in dialysis patients with and without DM [continuous outcomes] Supplemental Table 13: Evidence profile of RCTs examining the effect of statins vs. placebo in dialysis patients with and without DM Supplemental Table 14: Summary table of RCT examining statin vs. placebo in patients with ADPKD [continuous outcomes] Supplemental Table 15: Summary table of RCT examining simvastatin/ ezetimibe combination vs. simvastatin/placebo in CKD patients without DM [categorical outcomes] Supplemental Table 16: Summary table of RCT examining simvastatin/ ezetimibe combination vs. simvastatin/placebo in CKD patients without DM [continuous outcomes] Supplemental Table 17: Summary table of RCT of statin ezetimibe vs. placebo in CKD patients [categorical outcomes] Supplemental Table 18: Summary table of RCT examining the effect of dose of atorvastatin in CKD patients with DM [categorical outcomes] Supplemental Table 19: Drug interactions Supplemental Table 20: Effects of grapefruit juice on statin pharmacokinetics and recommendations Supplemental Table 21: Patients on statin fibrate therapy reporting any adverse event Supplemental Table 22: Patients receiving statin fibrate therapy reporting other individual adverse events Supplemental Table 23: Patients on statin fibrate therapy reporting treatment related adverse events Supplemental Table 24: Patients on statin fibrate therapy discontinuing due to adverse events Supplemental Table 25: Patients on statin fibrate therapy with increased ALT or AST Supplemental Table 26: Patients on statin fibrate therapy with increased CK Supplemental Table 27: Patients on statin fibrate therapy with increased serum creatinine Supplemental Table 28: Patients receiving statin fibrate therapy reporting rhabdomyolysis Supplemental Table 29: Summary table of RCTs of statin vs. placebo in kidney transplant patients [categorical outcomes] Supplemental Table 30: Summary table of RCTs of statin vs. placebo in kidney transplant patients [continuous outcomes] Supplemental Table 31: Evidence profile of RCTs examining the effect of statins vs. placebo in kidney transplant recipients Supplementary material is linked to the online version of the paper at http://www.kdigo.org/home/guidelines/lipids Chapter 3: Assessment of lipid status in children with CKD 3.1: In children with newly identified CKD (including those treated with chronic dialysis or kidney trans- plantation), we recommend evaluation with a lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides). 